Be Ready to Dispense Paxlovid or Molnupiravir for COVID-19
February 2022
You'll start to see Rxs for two new oral antivirals to treat COVID-19, Paxlovid (nirmatrelvir/ritonavir) or molnupiravir.
Either is an option for patients with mild to moderate COVID-19 who are at high risk of developing serious illness (age 65 or older, diabetes, etc)...regardless of vaccination status.
Be ready to handle these Rxs correctly...and ensure safe use.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote